Back to search

Article

Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial

2026-04-04

Abstract excerpt

<h4>Background</h4> There are no licensed treatments for patients with mild-to-moderate patchy alopecia areata (AA). <h4>Objectives</h4> To evaluate the efficacy, safety and dose-response of STS01, a novel nanoparticle controlled-release, topical formulation of dithranol/Prosilic. <h4>Methods</h4> In a phase 2, double-blind study, adult patients with mild-to-moderate AA (guideline ≥10% to ≤50% of scalp hair los...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e6e42473-ba6e-5e9d-925b-07b91876a7ab
DOI
10.64898/2026.04.02.26349934
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trialDOI 10.64898/2026.04.02.26349934
Select a neighboring publication to make it the new centre.